Taguchi T, Ohta K, Hotta T, Shirakawa S, Masaoka T, Kimura I
Osaka University.
Gan To Kagaku Ryoho. 1997 Aug;24(10):1263-71.
A late Phase II multicenter study with menogaril was conducted nationwide in patients with malignant lymphoma [non-Hodgkin's lymphoma (NHL), Hodgkin's disease (HD)], and ATLL, menogaril was orally administered at 100 mg daily after breakfast, for seven consecutive days with two- or three-week drug withdrawal, then menogaril administration was repeated. For malignant lymphoma, in 81 patients with NHL and 5 patients with HD registered, 70 and 5 patients were evaluable for efficacy, respectively. The efficacy rates were 32.9% (6 CRs + 17 PRs/70) for NHL and 20.0% (1 PR/5) for HD, respectively; that for the NHL patients with prior anthracycline antibiotic chemotherapy was 30.5% (5 CRs and 13 PRs/59). For ATLL, among the 16 patients registered, 15 were evaluable for efficacy, and the efficacy rate was 40.0% (2 CRs and 4 PRs/15). Adverse drug reactions frequently observed in the patients with malignant lymphoma and ATLL included bone-marrow suppression and gastrointestinal symptoms such as anorexia, and nausea/vomiting. With these results, menogaril was considered to be effective for the treatment of non-Hodgkin's lymphoma and ATLL.
一项关于美诺立尔的多中心II期晚期研究在全国范围内针对恶性淋巴瘤患者（非霍奇金淋巴瘤（NHL）、霍奇金病（HD））以及成人T细胞白血病/淋巴瘤（ATLL）开展。美诺立尔早餐后口服，每日100毫克，连续服用7天，停药2至3周后重复给药。对于恶性淋巴瘤，在登记的81例NHL患者和5例HD患者中，分别有70例和5例可评估疗效。NHL的有效率分别为32.9%（6例完全缓解 + 17例部分缓解/70例），HD为20.0%（1例部分缓解/5例）；既往接受过蒽环类抗生素化疗的NHL患者有效率为30.5%（5例完全缓解和13例部分缓解/59例）。对于ATLL，在登记的16例患者中，15例可评估疗效，有效率为40.0%（2例完全缓解和4例部分缓解/15例）。恶性淋巴瘤和ATLL患者中经常观察到的药物不良反应包括骨髓抑制以及胃肠道症状，如厌食、恶心/呕吐。基于这些结果，美诺立尔被认为对非霍奇金淋巴瘤和ATLL的治疗有效。
